Clinical Trials List
2012-12-01 - 2016-05-31
Phase III
Study ended8
ICD-10I25.10
Atherosclerotic heart disease of native coronary artery without angina pectoris
ICD-9429.2
Cardiovascular disease, unspecified
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Tse-Min Lu Division of Cardiovascular Diseases
- Shih-Hsien Sung Division of Cardiovascular Diseases
- 林幸榮 Division of Cardiovascular Diseases
- Kang-Ling Wang Division of Cardiovascular Diseases
- Wen-Chung Yu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Study ended
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- 林時逸 Division of Endocrinology
- 張心玫 Division of Endocrinology
- 李昂澤 Division of Endocrinology
- I-TE LEE Division of Endocrinology
- 蘇碩偉 Division of Endocrinology
- 黃怡文 Division of Endocrinology
- JUN-SING WANG Division of Endocrinology
- 陳拓邦 Division of Endocrinology
- 蔡婉妮 Division of Endocrinology
- 傅家保 Division of Endocrinology
- 李佳霖 Division of Endocrinology
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- 曾春典 Division of Cardiovascular Diseases
- JYH-MING JIMMY JUANG Division of Cardiovascular Diseases
- Juey-Jen Hwang Division of Cardiovascular Diseases
- LIAN-YU LIN Division of Cardiovascular Diseases
- CHIA-TI TSAI Division of Cardiovascular Diseases
- CHO-KAI WU Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Study ended
The Actual Total Number of Participants Enrolled
0 Study ended
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- 蔡青峰 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- 朱志生 Division of Cardiovascular Diseases
- Tsung-Hsien Lin Division of Cardiovascular Diseases
- Ye-Hsu Lu Division of Cardiovascular Diseases
- 顏學偉 Division of Cardiovascular Diseases
- 溫文才 Division of Cardiovascular Diseases
- Po-Chao Hsu Division of Cardiovascular Diseases
- 鄭凱鴻 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Study ended
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
180 participants
-
Global
11000 participants
